HX009

DRUG3 trials

Sponsors

Waterstone Hanxbio Pty Ltd, Hangzhou Hanx Biopharmaceuticals, Ltd.

Conditions

Advanced Solid TumorAdvanced Solid Tumors

Phase 1

The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies

CompletedNCT04097769

Waterstone Hanxbio Pty LtdAdvanced Solid Tumor

Start: 2019-06-12End: 2022-09-29Updated: 2022-12-12

Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors

Active, not recruitingNCT05731752

Hangzhou Hanx Biopharmaceuticals, Ltd.Advanced Solid Tumors

Start: 2020-05-28End: 2024-12-30Target: 80Updated: 2024-07-22

Phase 2

Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors

CompletedNCT04886271

Hangzhou Hanx Biopharmaceuticals, Ltd.Advanced Solid Tumor

Start: 2021-05-12End: 2024-02-22Updated: 2026-04-15

Related Papers

A phase 1b study investigating the safety, tolerability and preliminary efficacy of HX009 in post-immune checkpoint inhibitor (CPI) therapy advanced melanoma patients.

Journal of Clinical Oncology2025-05-28

A Phase Ib Clinical Trial Investigating the Safety, Tolerability, and Pharmacokinetics of HX009，a Novel Bsab Dual Targeting PD-1 x CD47，in Patients with EBV+ Non-Hodgkin Lymphoma (NHL)

Blood2024-11-05

First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

Journal of Clinical Oncology2021-05-2032 citations